TD Cowen Maintains Buy on Caris Life Sciences, Raises Price Target to $36
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
TD Cowen analyst Dan Brennan maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and raises the price target from $30 to $36.
TD Cowen analyst Dan Brennan maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and raises the price target from $30 to $36.